Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus.
The report details the trend, potential and market size of Uterine Cancer Therapies and Diagnostic market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Uterine Cancer Therapies and Diagnosticmarket, defines the market attractiveness level of Uterine Cancer Therapies and Diagnostic market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Uterine Cancer Therapies and Diagnostic industry, describes the types of Uterine Cancer Therapies and Diagnostic market, the applications of major players and the market size, and deeply analyzes the current situation of the global Uterine Cancer Therapies and Diagnostic market and the development prospects and opportunities of Uterine Cancer Therapies and Diagnostic industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Uterine Cancer Therapies and Diagnostic market in Chapter 13.
By Player:
AbbVie
BD
Ariad Pharmaceuticals
Merck
By Type:
Uterine Sarcomas
Endometrial Carcinomas
By End-User:
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Uterine Cancer Therapies and Diagnostic Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Uterine Cancer Therapies and Diagnostic Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Uterine Cancer Therapies and Diagnostic Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Uterine Cancer Therapies and Diagnostic Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Uterine Cancer Therapies and Diagnostic Market Analysis and Outlook to 2022
-
7.1 Global Uterine Cancer Therapies and Diagnostic Consumption (2017-2022)
-
7.2 United States Uterine Cancer Therapies and Diagnostic Consumption (2017-2022)
-
7.3 Europe Uterine Cancer Therapies and Diagnostic Consumption (2017-2022)
-
7.4 China Uterine Cancer Therapies and Diagnostic Consumption (2017-2022)
-
7.5 Japan Uterine Cancer Therapies and Diagnostic Consumption (2017-2022)
-
7.6 India Uterine Cancer Therapies and Diagnostic Consumption (2017-2022)
-
7.7 South Korea Uterine Cancer Therapies and Diagnostic Consumption (2017-2022)
8 Region and Country-wise Uterine Cancer Therapies and Diagnostic Market Analysis and Outlook to 2028
-
8.1 Global Uterine Cancer Therapies and Diagnostic Consumption Forecast (2022-2028)
-
8.2 United States Uterine Cancer Therapies and Diagnostic Consumption Forecast (2022-2028)
-
8.3 Europe Uterine Cancer Therapies and Diagnostic Consumption Forecast (2022-2028)
-
8.4 China Uterine Cancer Therapies and Diagnostic Consumption Forecast (2022-2028)
-
8.5 Japan Uterine Cancer Therapies and Diagnostic Consumption Forecast (2022-2028)
-
8.6 India Uterine Cancer Therapies and Diagnostic Consumption Forecast (2022-2028)
-
8.7 South Korea Uterine Cancer Therapies and Diagnostic Consumption Forecast (2022-2028)
9 Global Uterine Cancer Therapies and Diagnostic Market Outlook by Types and Applications to 2022
-
9.1 Global Uterine Cancer Therapies and Diagnostic Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Uterine Sarcomas Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Endometrial Carcinomas Consumption and Growth Rate (2017-2022)
-
9.2 Global Uterine Cancer Therapies and Diagnostic Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Specialty Clinics Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Others Consumption and Growth Rate (2017-2022)
10 Global Uterine Cancer Therapies and Diagnostic Market Outlook by Types and Applications to 2028
-
10.1 Global Uterine Cancer Therapies and Diagnostic Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Uterine Sarcomas Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Endometrial Carcinomas Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Uterine Cancer Therapies and Diagnostic Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Specialty Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Uterine Cancer Therapies and Diagnostic Import and Export Analysis (Top 5 Countries)
-
11.1 Global Uterine Cancer Therapies and Diagnostic Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Uterine Cancer Therapies and Diagnostic Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Uterine Cancer Therapies and Diagnostic Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Uterine Cancer Therapies and Diagnostic Market Competitive Analysis
-
14.1 AbbVie
-
14.1.1 AbbVie Company Details
-
14.1.2 AbbVie Uterine Cancer Therapies and Diagnostic Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 AbbVie Uterine Cancer Therapies and Diagnostic Product and Service
-
14.2 BD
-
14.2.1 BD Company Details
-
14.2.2 BD Uterine Cancer Therapies and Diagnostic Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 BD Uterine Cancer Therapies and Diagnostic Product and Service
-
14.3 Ariad Pharmaceuticals
-
14.3.1 Ariad Pharmaceuticals Company Details
-
14.3.2 Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Product and Service
-
14.4 Merck
-
14.4.1 Merck Company Details
-
14.4.2 Merck Uterine Cancer Therapies and Diagnostic Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Merck Uterine Cancer Therapies and Diagnostic Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Uterine Cancer Therapies and Diagnostic
-
Figure Uterine Cancer Therapies and Diagnostic Picture
-
Table Global Uterine Cancer Therapies and Diagnostic Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Uterine Cancer Therapies and Diagnostic Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Uterine Cancer Therapies and Diagnostic Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Uterine Cancer Therapies and Diagnostic Consumption by Country (2017-2022)
-
Figure United States Uterine Cancer Therapies and Diagnostic Consumption and Growth Rate (2017-2022)
-
Table Europe Uterine Cancer Therapies and Diagnostic Consumption and Growth Rate (2017-2022)
-
Figure China Uterine Cancer Therapies and Diagnostic Consumption and Growth Rate (2017-2022)
-
Figure Japan Uterine Cancer Therapies and Diagnostic Consumption and Growth Rate (2017-2022)
-
Figure India Uterine Cancer Therapies and Diagnostic Consumption and Growth Rate (2017-2022)
-
Figure South Korea Uterine Cancer Therapies and Diagnostic Consumption and Growth Rate (2017-2022)
-
Figure Global Uterine Cancer Therapies and Diagnostic Consumption Forecast by Country (2022-2028)
-
Figure United States Uterine Cancer Therapies and Diagnostic Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Uterine Cancer Therapies and Diagnostic Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Uterine Cancer Therapies and Diagnostic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Uterine Cancer Therapies and Diagnostic Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Uterine Cancer Therapies and Diagnostic Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Uterine Cancer Therapies and Diagnostic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Uterine Sarcomas Consumption and Growth Rate (2017-2022)
-
Figure Global Endometrial Carcinomas Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)
-
Figure Global Specialty Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Uterine Sarcomas Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Endometrial Carcinomas Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Specialty Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Uterine Cancer Therapies and Diagnostic Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Uterine Cancer Therapies and Diagnostic Export by Region (Top 5 Countries) (2017-2028)
-
Table AbbVie (Foundation Year, Company Profile and etc.)
-
Table AbbVie Uterine Cancer Therapies and Diagnostic Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Uterine Cancer Therapies and Diagnostic Product and Service
-
Table BD (Foundation Year, Company Profile and etc.)
-
Table BD Uterine Cancer Therapies and Diagnostic Sales, Price, Value and Gross Profit (2017-2022)
-
Table BD Uterine Cancer Therapies and Diagnostic Product and Service
-
Table Ariad Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ariad Pharmaceuticals Uterine Cancer Therapies and Diagnostic Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck Uterine Cancer Therapies and Diagnostic Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Uterine Cancer Therapies and Diagnostic Product and Service
-
